Autres langues Dr. Lal PathLabs Limited

Actions

LALPATHLAB

INE600L01024

Temps Différé NSE India S.E. Autres places de cotation 07:26:58 03/06/2024			Varia. 5j.	Varia. 1 janv.
2 657 ^INR	+0,35 %		+1,01 %	+3,15 %

14/05	DR. LAL PATHLABS LIMITED : Nomura adopte une opinion positive	ZM
13/05	Le bénéfice net consolidé de Dr. Lal Pathlabs augmente au quatrième trimestre fiscal ; l'action progresse de 6%.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

DR. LAL PATHLABS LIMITED : Nomura adopte une opinion positive	14/05
Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6%	13/05
Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024	10/05
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand	10/05
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	10/05
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	10/05
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	26/04
Dr Lal Pathlabs Names CEO	18/03
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	17/03
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	03/03
DR. LAL PATHLABS LIMITED : Jefferies & Co. est neutre sur le titre	05/02
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	02/02
Dr. Lal PathLabs Seeks M&A	01/02
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	01/02
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	01/02
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	01/02
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01/02
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	25/01
DR. LAL PATHLABS LIMITED : Nomura revoit son opinion et passe à neutre	06/11
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Dr. Lal PathLabs Limited

Actions

LALPATHLAB

INE600L01024

Autres langues

Filtres